# Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
Canonical URL: https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-initiation-of-patient-dosing-in-first-of-its-kind-phase-3-head-to-head-car-t-cell-clinical-trial-in-aggressive-large-b-cell-lymphoma
Ticker: LYEL
Company: Lyell Immunopharma
Source: Lyell Immunopharma
Published: 2026-02-12 12:30 EST
Original Source URL: https://ir.lyell.com
## Summary

PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line setting The pivotal single-arm trial, PiNACLE,

## Article Body
PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line setting The pivotal single-arm trial, PiNACLE,
## Recent Company News
- 2026-06-01 12:00 EST — [Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Lyell Immunopharma
- 2026-05-12 12:00 EST — [Lyell Immunopharma Announces Participation in May Investor Conferences](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-may-investor-conferences) — Source: Lyell Immunopharma
- 2026-05-06 20:05 EST — [Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026) — Source: Lyell Immunopharma
- 2026-04-07 12:00 EST — [Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference) — Source: Lyell Immunopharma
- 2026-03-12 20:05 EST — [Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-q4-and-full-year-2025-business-and-financial-results) — Source: Lyell Immunopharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)